Hormonal Contraception and HIV Risk: Understanding the ECHO trial

The Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study is an open-label, randomized, clinical trial comparing three highly effective, reversible methods of contraception — the progestogen-only injectable depot-medroxyprogesterone acetate (DMPA), a levonorgestrel implant, and the non-hormonal copper intrauterine device — to evaluate whether there is any difference in the risk of acquiring HIV infection among users of these methods.

Results, expected in mid-2019, will help guide the implementation of safe, effective policies and services that will enable women at high risk of HIV to make fully informed choices about contraception and HIV prevention.

The webinar featured:

Beth Schlachter, Executive Director, FP2020
Dr. Jared Baeten, Vice Chair, Department of Global Health, University of Washington, ECHO Consortium
Dr. Nelly Mugo, Research Associate Professor, Global Health, University of Washington, ECHO Management Committee
Tamar Abrams, Communications Director, FP2020

You may view the webinar here.

HIV Vaccine Research and Development Pipeline: 2019 Supplement

A slide deck overview of what’s happening in HIV vaccine research now.

Vaccine Strategies in the Pipeline

Scientists are studying these strategies to develop an effective vaccines and deliver it into the body in a way that maximizes the immune response.

HIV-Specific Neutralizing Antibodies – Targets and research status

Numerous studies, both early and late phase, are investigating the efficacy of neutralizing antibodies. This infographic shows the ongoing studies and the differing locations they target on the virus.

Total Vaccine Spending by Area

A look at the percentage of total funds invested in different aspects of vaccine research.

Vaccines Trial Participation in 2019

A look at the number of participants in vaccines trials in 2019 according to trial phase.

The Science of Choice: The future of HIV prevention research

This episode of Px Pulse features unmissable conversations about some of the challenges associated with today’s HIV prevention options, and analysis about what should be in the research pipeline from 2021 to 2027.

Regulatory Status of TDF/FTC for PrEP

The TDF/FTC combination pill (brand-name Truvada) that has shown efficacy for PrEP is already used for Treatment U=U in HIV-positive people, and so is approved and licensed in many countries. One key step for this PrEP strategy is to ensure that the drug is licensed (and therefore available) and that it is approved for use for both prevention and Treatment U=U in each country. National guidelines for PrEP use are another key step.

Px Wire July-December 2018, Vol. 11, No 3

As 2018 winds down, we’re struck by the many moments, and movements, in the past year that have depended on listening, without bias and also without loss of conviction. In that spirit, our year-end edition of Px Wire offers 10 questions for activists to pose, with curiosity and conviction, in 2019. What answers do you want, what do you hear, what needs to happen next?

HIV Prevention Research and Demonstration Sites in South Africa

This map demonstrates the breadth of HIV prevention research and demonstration projects in South Africa by site and type (e.g. daily oral PrEP demo projects, ARV-based rings, long-acting injectable PrEP, preventative Vaccines, antibodies, hormonal contraceptives). This map was developed by Wits RHI with support from AVAC as part of the Coalition to Accelerate and Support Prevention Research. This graphic first appeared in AVAC Report 2017: Mixed messages and how to untangle them.